Harvard Bioscience (HBIO) Other Accumulated Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Other Accumulated Expenses data on file, last reported at $2.1 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $2.1 million, up 37.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 million (up 37.77% YoY), and the FY2025 annual result was $14.9 million, up 1104.29% from the prior year.
• Other Accumulated Expenses eased to $2.1 million in Q1 2026 per HBIO's latest filing, from $14.9 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $14.9 million in Q4 2025 and troughed at $956000.0 in Q3 2022.
• A 5-year average of $5.8 million and a median of $4.8 million in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses sank 90.88% in 2022, then surged 1104.29% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $982000.0 in 2022, then surged by 981.57% to $10.6 million in 2023, then plunged by 88.38% to $1.2 million in 2024, then surged by 1104.29% to $14.9 million in 2025, then slumped by 86.13% to $2.1 million in 2026.
• Business Quant data shows HBIO's Other Accumulated Expenses at $2.1 million in Q1 2026, $14.9 million in Q4 2025, and $1.6 million in Q3 2025.